Analysts Expect AzurRx BioPharma Inc (NASDAQ:AZRX) to Announce -$0.09 Earnings Per Share

Equities research analysts forecast that AzurRx BioPharma Inc (NASDAQ:AZRX) will post ($0.09) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for AzurRx BioPharma’s earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.11). AzurRx BioPharma posted earnings per share of ($0.17) in the same quarter last year, which would suggest a positive year over year growth rate of 47.1%. The company is expected to announce its next quarterly earnings report on Thursday, November 12th.

According to Zacks, analysts expect that AzurRx BioPharma will report full-year earnings of ($0.56) per share for the current year, with EPS estimates ranging from ($0.64) to ($0.40). For the next year, analysts anticipate that the firm will report earnings of ($0.35) per share, with EPS estimates ranging from ($0.42) to ($0.29). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for AzurRx BioPharma.

Separately, Maxim Group reiterated a “buy” rating and set a $3.00 price objective on shares of AzurRx BioPharma in a research note on Thursday, August 13th.

AZRX stock traded down $0.02 during trading on Friday, hitting $0.70. 148,854 shares of the company’s stock traded hands, compared to its average volume of 388,199. AzurRx BioPharma has a 1 year low of $0.37 and a 1 year high of $1.94. The business has a fifty day simple moving average of $0.82 and a two-hundred day simple moving average of $0.80.

AzurRx BioPharma Company Profile

AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.

Read More: Blockchain

Get a free copy of the Zacks research report on AzurRx BioPharma (AZRX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for AzurRx BioPharma (NASDAQ:AZRX)

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with's FREE daily email newsletter.